 |
|
|
| |
Real-world effectiveness and cost per SVR of
Sofosbuvir/Velpatasvir in chronic hepatitis C treatment / GT3
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Peter Buggisch1, Petar Atanasov2, Karsten Wursthorn1, Albrecht Stoehr1, Jorg Petersen1
1Asklepios Klinik St. Georg, IFI Institut fur Interdisziplinäre Medizin, Hamburg, Germany 2Amaris, London, United Kingdom
|
| |
|
|
|
|
|
